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ABSTRACT
Diabetic retinopathy (DR) is a visual disorder caused by the diabetic microvascular complications.
Genetic polymorphism in the vascular endothelial growth factor (VEGF) gene plays an importan
role in the susceptibility of DR. The aim of this study was to evaluate the association of the
polymorphism of VEGF gene insetion/deletion (I/D) -2549 with DR in Javanese type 2 diabetes
mellitus (DM) patients. This was a case control study involving 40 Javanese type 2 DM patients
with DR as case subjects and 40 Javanese type 2 DM patients without DR as control subjects.
Type 2 DM patients with DR were recruited from Eye Polyclinic, whereas type 2 DM patients
without DR were recruited from Endocrine Polyclinic of Dr. Sardjito General Hospital, Yogyakarta.
Genotyping of VEGF gene I/D-2549 was conducted using PCR-RFLP method. Plasma VEGF
levels were measured using Enzym-Linked Immunosorbent Assay (ELISA). The genotype distribution
of DD (67.5%) and the allele frequency of D (82.5%) in type 2 DM patients with DR was higher
than those without DR (27.5% for DD genotype and 56.3% for D allele). The OR of DD and ID
genotypes versus II genotype between type 2 DM patients with DR and without DR was 6.882
(95%CI: 0.789-60.060; p=0.048), whereas OR for the D allele versus I allele between type 2 DM
patients with DR and without DR was 3.667 (95%CI: 1.773-3.667; p=0.000). The plasma VEGF
levels of DD genotype (92.16±49.73 pg/mL) were significantly higher than ID genotype
(42.70±33.29 pg/mL) in type 2 DM patients (p=0.000). In conclusion, the polymorphism of
VEGF gene I/D -2549 is associated with DR in Javanese type 2 DM patients. The DD genotype
and D allele of the VEGF gene polymorphism are the risk factor of DR in those patients. The
association of the polymorphism of VEGF gene with DR may be explained with the high plasma
VEGF level.
ABSTRAK
Retinopati diabetes (RD) adalah gangguan visual akibat komplikasi mikrovaskular pada diabetes.
Poliorfisme genetik di gen VEGF berperan penting terhadap terjadinya RD. Tujuan penelitian ini
adalah untuk mengkaji hubungan polimorfisme insersi/delesi -2549 gena VEGF dengan kejadian
RD pada penderita DM tipe 2 suku Jawa. Penelitian ini merupakan penelitian potong lintang
yang melibatkan 40 penderita DM tipe 2 dengan RD sebagai kasus dan 40 penderita DM tipe 2
tanpa RD sebagai kontrol. Penderita DM tipe 2 dengan RD direkrut dari Poliklinik Mata, sedangkan
penderita DM tipe 2 tanpa RD direkrut dari Poliklinik Endokrin, Rumash Sakit Umum Dr. Sardjito,
Yogyakarta. Genotiping I/D -2549 gena VEGF dilakukan menggunakan metode PCR-RFLP. Kadar
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VEGF plasma ditetapkan menggunakan metode Enzym-Linked Immunosorbent Assay (ELISA).
Distribusi genotip DD (67,5%) dan frekuensi alel D (82.5%) pada penderita DM tipe 2 dengan
RD lebih tinggi dibandingankan dengan tanpa RD (27,5% untuk genotip DD dan 56,3% untuk
alel D). Nilai OR genotip DD dan ID dibandingakan genotip II antara penderita DM tipe 2 dengan
RD dan tanpa RD adalah 6,882 (95%CI: 0,789-60,060; p=0,048). Sedangkan nilai OR untuk alel
D dibandingkan alel Iantara penderita DM tipe 2 dengan RD dan tanpa RD adalah 3,667 (95%CI:
1,773-3,667; p=0,000). Kadar VEGF plasma genotip DD (92,16±49,73 pg/mL) lebih tinggi
secara bermakna dibandingkan genotip ID (42,70±33,29 pg/mL) pada penderita DM tipe 2
(p=0,000). Dari hasil penelitian ini dapat disimpulkan polimorfisme I/D -2549 gena VEGF berkaitan
dengan kejadian RD pada penderita DM tipe 2. Genotip DD dan alel D polimorfisme gena VEGF
merupakan faktor risiko RD pada pasien DM. Hubungan polimorfisme gena VEGF dengan RD
kemungkinan berkaitan dengan tingginya kadar VEGF plasma.
Keywords: vascular endothelial growth factor (VEGF) - polymorphism - diabetes - retinopathy
- Javanese patients
INTRODUCTION
Diabetes Mellitus (DM) is a chronic
disease, which occurs when the pancreas does
not produce enough insulin or when the body
can not effectively use the insulin. Diabetes
mellitus leads to increased blood glucose level
or hyperglycaemia.1 Hyperglycaemia is a risk
factor in diabetic microvascular complications
which are the major cause of morbidity and
early mortality in diabetes.2-4 Diabetic
retinopathy (DR) is a visual disorder caused
by the diabetic microvascular complications. It
is characterized by vascular permeability, tissue
ischemia and neovascularisation. During
hypoxia, hypoxia inducible factors bind to the
hypoxia-response and induce the expression of
VEGF which leads to the stimulation of
angiogenesis and increases of microvascular
permeability.5-7
Genetic factors have been proven to be able
to influence in the susceptibility to diabetic
nephropathy and retinopathy.8 Vascular
endothelial growth factor (VEGF) is disulfide-
linked dimer glycoprotein or homodimeric
glycoprotein, which plays an important role in
the pathogenesis of DR. VEGF promotes
angiogenesis, stimulates endhotelial disfunct-
ions and increases microvascular permeability
in many type of tissues including retinal blood
vessel.6-8
Genetic polymorphism in the VEGF gene
that influences its VEGF protein expression
level has been reported.4-8 The human VEGF
gene that is located on chromosome 6 (6p21.3)
and consists of 8 exons and 7 introns is highly
polymorphic. Several different isoforms of
VEGF gen have been reported.9 One of the
isoforms of VEGF gen that is associated with
DR is insertion/deletion (I/D) polymorphism of
the 18 bp fragment at -2549 posistion of the
promoter region. Buraczynska et al.12 suggested
that the polymorphism of VEGF gene I/D -2549
is associated with DR in Caucasian type 2 DM
patients. However, no significant association
between the polymorphism of VEGF gene I/D -
2549 and DR was observed in Egyptian type 2
DM patients.7
The studyconcerning genetic polymorphism
of VEGF gene, especially I/D polymorphism at
-2549 position in the association with DR in
Indonesian DM patients has not been reported
yet. The objective of this study was to
investigate the association of the polymorphism
of VEGF gene I/D -2549 with DR in a Javenese
population with type 2 DM.
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MATERIALS AND METHODS
Subjects
This was a case control study involving 40
Javanese type 2 DM patients with DR as case
and 40 Javanese type 2 DM patients without
DR as control subjects. Type 2 DM patients with
DR were recruited from Eye Polyclinic, whereas
type 2 DM patients without DR were recruited
from Endocrine Polylinic of Dr. Sardjito
General Hospital, Yogyakarta. Subjects aged
30-65 years, were diagnosed with type 2 DM 5
for at least 5 years, did not suffer from hyper-
tension and were neither obese nor dyslipi-
demia. Informed consent was obtained from
each participant, and the study was approved
by the Medical and Health Research Ethics
Committee, Universitas Gadjah Mada, Yogya-
karta.
Screening of DM and DR
The diagnosis and calassification of DM
was based on clinical and laboratory examinat-
ion and the guidelines in the recent Expert
Committee Report of the American Diabetes
Association. Subjects were diagnosed DM if
the fasting plasma glucose (FPG)126 mg/dL
or random plasma glucose (RPG)200 mg/dL
or the oral glucose tolerance test (OGTT) 
200 mg/dL.
The diagnosis DR was performed by
independent opthalmologist based on fundus
photographyand the EarlyTreatment of Diabetic
Retinopathy Study (ETDRS) protocol. Subject
was considered DR if it was found at least one
of retinophaty signs namely microaneurism,
abnormality of intraretinal microvascular,
venouse beading/looping, blot or dot bleeding,
soft exudate, hard exudates, neovascularisation
on pupil or other places, preretina bleeding and
retina fibrosis with or without edema macula.13
VEGF gene I/D -2549 polymorphisms
genotyping
Genotyping of VEGF gene I/D-2549 was
conducted using PCR-RFLP method as
conducted by Fouad et al.5 DNA sample was
isolated from buffy coat. The VEGF gene I/D -
2549 polymorphism was analyzed using the
following primers i.e. forward primer 5’–
GCTGAGAGTGGGGCTGACTAGGTA-3’and
reverse primer 5’-GTTTCTGACCTGGC-
TATTTCCAGG-3’. Genomic DNA was
amplified using the following PCR conditions
i.e early denaturation at 95 oC for 6 minutes
followed by further denaturation of 35 cycle at
94 oC for 1 minute, annealing at 60 oC for 1.5
minutes, and extention at 72 oC for 2 minutes.A
final extention was performed at 72 oC for 10
minutes. The amplification product was
separated by electrophoresis on agarose gel 3.2
% and visualized with ethidium bromide.
Elektrophoresis was carried out for 45 minutes,
with 100 volt and the result was observed with
UV ray. II genotype (homozygous mutation) had
1 band of 229 bp. DD genotype (wild type) had
also 1 band of 211 bp, while ID genotype
(heterozygous mutation) had 2 band of 229 bp
and 211 bp.12
Plasma VEGF concentrations assay
Plasma VEGF levels were measured using
Enzym-Linked ImmunosorbentAssay (ELISA)
as performed by Awata et al.14 A monoclonal
antibody specific for human VEGF has been
coated onto the 96-well microplate. One
hundred µL of plasma sample and standard of
known human VEGF concentration were
pipetted into these wells and then incubated at
room temperature for 2 hours. After washing
with wash buffer for twice to three times (400
µL each), 200 µL a polyclonal antibody anti
VEGF-HRP were added into these wells and
incubated again at room temperature for 2 hours.
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After washing again with wash buffer, 200 µL
substrate solution were added and incubated at
room temperature for 25 minutes. Following the
incubation, 50 µL stop solution were added in
these wells. The solution in the microplate was
mixed by shaking it gently. Optic density of the
microculture plates was then measured in an
ELISA plate reader at l 450 nm. The standard
curve was made and used to determine the
VEGF plasma level in the unknown samples.
Statistical analysiss
Depending on the types of data, data were
expressed as mean ± standard deviation (SD)
for quantitative variables and as number and
percentage for qualitative values. Variables
including age, IMT, SBP, DBP, FPG, OGTT,
triglyceride, total cholesterol and HDL
cholesterol were analyzed using independent t-
test or Mann Whitney test. Statistical differences
between genotype distribution were tested using
Chi-square (÷2) test and betweenplasma VEGF
level were tested using independent t-test.
Associations of genotypes and alleles were
assessed as OR and 95% confidence intervals
(95% CI). Differences by univariate methods
(÷2 test, independent t-test) were analyzed
together in a logistic regression analysis to test
the significant risk factors for diabetic
retinopathy. All statistical analysis were
considered significant if p value < 0.05.
RESULTS
The characteristics of subjects both type 2
DM patients with DR and without DR are
presented in TABLE 1. No statistically
significant difference in age between type 2 DM
with and withour DR was observed (p = 0.272).
Moreover, the distribution of gender was
TABLE 1. Characteristics of type 2 DM patients with and without DR
Data are n (%); Values are presented as mean ± standard deviation (SD); DM: diabetes melli-
tus; DR: diabetic retinopathy; statistical analysis uses independent t-test or Mann Whitney
test depending on the type of data
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similar in type 2 DM with DR and without DR.
With regard to clinical characteristics, patients
of type 2 DM with DR and without DR were
not different except for OGTT where type 2 DM
patients with DR had a significantly higher
plasma glucose level after OGTT than type 2
DM patients without DR (p = 0.041).
PCR amplification products of VEGF gene
I/D -2549 polymorphism for type 2 DM patients
with and without DR are presented in FIGURE
1. Wild type genotypes (DD), homozygous
mutation (II) and heterozygous mutation (ID)
were observed in both type 2 DM patients with
DR and without DR (FIGURE 1).
The genotype distributions (DD, ID and II)
and allele frequencies (D and I) of VEGF gene
I/D -2549 polymorphism in type 2 DM patients
with and without DR are presented in TABLE
1. The genotype distributions did not deviate
significantly from the Hardy-Weinberg
equilibrium (p=.986). In type 2 DM patients
with DR, the genotype distribution of DD was
highest followed by ID and II (p=0.001).
Moreover, the allele frequency of D was higher
than I (p=0.001), while in type 2 DM patients
without DR, the highest genotype distribution
was ID followed by DD and II (p=0.001).
However, the allele frequency of D was also
higher than I (p=0.001). Further analysis
showed that the genotype distribution of DD and
allele frequency of D in type 2 DM with DR
were higher than in type 2 DM without DR
(p=0.001). Conversely, the genotype distribution
of ID and II and allele frequency of I were lower
(p=0.001). The OR of DD and ID genotypes
versus II genotype between type 2 DM patients
with DR and without DR was 6.882 (95%CI:
0.789-60.060; p=0.048), whereas OR for the
D allele versus I allele between type 2 DM
patients with DR and without DR was 3.667
(95%CI: 1.773-3.667; p=0.000).
FIGURE 1. PCR amplification products of VEGF I/D -2549 gene polymorphism for
type 2 DM patients. M: PCR marker of 100 bp; 64-70: patients number;
DD: wild type; ID: heterozygous mutation; II: homozygous mutation
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TABLE 2. Genotype distribution and allele frequencies of VEGF gene I/D-2549 polymorphism
in type 2 DM patients with and without DR
Data are n (%); : statistical analysis uses Pearson’s Chi square (÷2) test
In order to evaluate the influence of the
VEGF gene I/D -2549 polymorphism of type 2
DM patients on VEGF gene expression, the
plasma VEGF levels were measured. Among
80 plasma samples obtained from all type 2 DM
patients, only 27 samples from patients with the
DD genotype and 29 samples from patients with
the ID genotype in which the plasma VEGF level
could be measured. Plasma VEGF level in
patients with II genotype could not be
determined due to damaged samples during
storage. The plasma VEGF levels of DD
genotype were significantly higher than ID
genotype in all type 2 DM patients (p=0.000)
as shown on TABLE 3. Moreover, a significantly
higher plasma VEGF levels of DD genotype
compare to ID genotype in type 2 DM with DR
(p=0.000) was also observed in this study
(TABLE 4).
TABLE 3. Plasma VEGF levels of DD and II genotypes of all type 2 DM patients
Values are presented as mean ± standard deviation (SD); Statistical analysis uses independent t-test
TABLE 4. Plasma VEGF levels of DD and ID genotype of type 2 DM patients with DR
Value are presented as mean ± standard deviation (SD); Statistical analysis uses independent
t-test
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The difference of the mean plasma VEGF
level between the type 2 DM patients with and
without DR was also evaluated (TABEL5). The
mean plasma VEGF level of type 2 DM patients
with DR was higher than patients without DR.
However, it was not significantly different
(p=0.0611). Further analysis was conducted to
evaluate the mean plasma VEGF levels in type
2 DM patients with poliferative diabetic
retinopathy (PDR) and with nonproliferative
diabetic retinopathy (NPDR). The results
showed that the mean plasma VEGF level of
type 2 DM patients with PDR was higher than
with NPDR, although it was also not
significantly different (p=0.611).
TABLE 5. Plasma VEGF levels of type 2 DM patients with and without DR
Values are presented as mean ± standard deviation (SD); Statistical analysis uses independent t-
test
TABLE 6. Plasma VEGF levels of type 2 DM patients wit PDR and NPDR
Values are presented as mean ± standard deviation (SD); Statistical analysis uses independent t-
test
DISCUSSION
In this study, the variables such as age, BMI,
blood pressure, FPG, OGTT, triglyceride, total
cholesterol, HDL and LDL cholesterol between
type 2 DM patients with and without DR were
controlled with matching. These variables can
be a risk factor of DR in type 2 DM patients.
Patients who aged more than 60 years have
higher the risk of retina disease, such as age-
related macular degeneration (AMD). Hyper-
tension is the risk factor of retinopathy hyper-
tension and dyslipidemia is a risk factor of
nonproliferative retinopathy. Statistical analysis
showed that the type 2 DM patients with DR
and without were not different except for OGTT
where type 2 DM patients with DR had a
significantly higher plasma glucose level after
OGTT than type 2 DM patients without DR (p
= 0.041).
Obesity was also controlled in this study
because obesity is often related to dyslipidemia.
However, duration of DM was a variable which
was difficult to control in this study. Riyanto15
reported that risk factor recall data have a
potential for recall bias. Moreover, medical
record as data resources was often incomplete
and even inaccurate. These were the limitations
of this study.
This study demonstrated the increase of
genotype distribution of DD and allele
frequency of D of the VEGF gene I/D
polymorphism in type 2 DM patients with DR
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compared with patients without DR suggesting
that DD genotype and D allele were the risk
factors for DR among Javenese type 2 DM
patients. It was found that there were almost 7
fold increase risk of DR associated with DD
and ID genotype between type 2 DM patients
with DR and without DR (OR:6.882; 95%CI:
0.789-60.060; p=0.048) and almost 4 fold
increase risk with D allele versus I allele
between type 2 DM patients with DR and
without DR (OR:3.667; 95%CI: 1.773-3.667;
p=0.000).
Studies concerning the VEGF gene I/D
polymorphism in association with DR in type 2
DM patients in different ethnic groups have been
reported by some authors. Buraczynska et al.12
reported that the polymorphism of VEGF gene
I/D -2549 is associated with retinopathy but not
nephropathy in Caucasian type 2 DM patients.
The DD genotype was significantly higher in
type 2 DM with DR compared with without DR
(44 vs 21%; p<0.01). Moreover, the D allele
of VEGF gene I/D polymorphism was an
independent risk factor of retinopathy with OR
of 2.27 (95%CI: 1.59-3.15). Otherwise, Fouad
et al.7 reported that the polymorphism of VEGF
gene I/D -2549 is not significantly associated
with retinopathyin Egyptian type 2 DM patients.
Despite no significant results, the DD genotype
was higher in type 2 DM with DR compared
with without DR (40.9 vs 27.9%; p=0.162).
Moreover, this study adjusted OR of 2.25 (95%
CI: 0.672- 7.538; p=0.185) for D/D genotype
versus I/I genotype between type 2 DM patients
with DR and healthy subjects and the OR of 1.6
(95% CI: 0.873- 2.891; p=0.129) for the D
allele versus I allele between type 2 DM with
DR and healthy subjects, while the OR of 1.2
(95% CI: 0.64- 2.29; p=0.539) the D ellele
versus I allele between type 2 DM without DR
patients and healthy subjects.
Diabetic retinopathy may be the most
common diabetic microvascular complication.
Diabetic retinopathy is characterized with
vascular permeability, tissue ischemia and
neovascularisation. VEGF plays an important
role in the pathogensis of diabetic microvascular
complications. During hypoxia, hypoxia
inducible factors bind to the hypoxia-response
and induce the VEGF expression which leads
to the stimulation of angiogenesis and increases
of microvascular permeability.6,7 Genetic
polymorphism in the VEGF gene has been
reported to influence the VEGF protein
expression level which is implicated in the
development of DR in DM patients.
In this study, the plasma VEGF level of all
subjects was measured and its association with
the VEGF gene polymorphism was also
evaluated. The results showed that there was a
strong association between DD genotype of
VEGF gene with the high plasma VEGF level.
This result is in agreement with the results
reported by some authors.16-18 In vitro and in
vivo study in animal model showed that the
presence of the D allele at -2549 in promotor
region of the VEGF gene leads to enhanced
expression of the gene.16,17 Other study also
showed that polymorphisms in the promotor
region of the VEGF gene affect the VEGF
production.18,19 Moreover, Yang et al.20 have
reported that there was an increase of the serum
VEGF levels in type 1 DM patients with DR
with the DD genotype compared with those with
the II genotype. Therefore, the association of
the DD genotype or D allele of the VEGF gene
with the susceptibility to DR among Javenese
type 2 DM patients can be explained with the
high plasma VEGF level.
CONCLUSION
In conclusion, the polymorphism of VEGF
gene I/D -2549 is associated with DR in
Javanese type 2 DM patients. The DD genotype
and D allele of the VEGF polymorphism are
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the risk factor of DR in those patients. The
association of the polymorphism of VEGF gene
I/D -2549 may be explained with the high
plasma VEGF level.
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